



Express Mail Label: EV 392131555 US  
Date of Deposit: August 2, 2004

Page 1 of 1  
Attorney Docket No.: 23254-507

Please type a plus sign (+) in this box

+

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number		10/626,085	
				Filing Date		July 24, 2003	
				First Named Inventor		Dhanoa	
				Group Art Unit		1614-1626	
				Examiner Name		Not Yet Assigned - Powers	
				Attorney Docket Number		24591-501	
<b>U.S. PATENT DOCUMENTS</b>							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
<b>U.S. PUBLISHED APPLICATION DOCUMENTS</b>							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
FTP	C31	Database Caplus on STN, Accession Number 1999:783937, Castelhana, et al., WO/99/62518 A1, CADUE PHARMACEUTICALS CORP. (1999).					
FTP	C32	Database Caplus on STN, Accession Number 2000:806616, Horvath, et al., 6,147,085, NEUROGEN CORPORATION (2000).					
FTP	C33	International Search Report for PCT/US03/23539, mailing date: July 23, 2004.					


A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	<i>Aiona T. Powers</i>	Date Considered	11/24/04
-----------------------	------------------------	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) in this box

+



Modified Form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/626,085
Filing Date	July 24, 2003
First Named Inventor	Becker
Group Art Unit	Not Yet Assigned 1620
Examiner Name	Not Yet Assigned POWERS
Attorney Docket Number	24591-501

## U.S. PATENT DOCUMENTS


Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
FTP	B1	WO 93/01160	Merck Sharp & Dohme Limited	01/21/93		
FTP	B2	WO 93/01165	Merck Sharp & Dohme Limited	01/21/93		
FTP	B3	WO 93/01169	Merck Sharp & Dohme Limited	01/21/93		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
FTP	C1	Goadsby, et al., "Substance P Blockade with the Potent and Centrally Acting Antagonist GR205171 does not Effect Central Trigeminal Activity with Superior Sagittal Sinus Stimulation", <i>Neuroscience</i> , 1998, 86(1):337-343.
	C2	Von Sprecher, et al., "Neurokinin Antagonists as Potential Therapies for Inflammation and Rheumatoid Arthritis", <i>Drugs</i> , 1998, 1(1):73-91.
	C3	Hill, R.G., "Role of Receptors in Nociception", <i>The Tachykinin Receptors</i> , ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 471-498.
	C4	Maggi, et al., "Tachykinin Receptors and Tachykinin Receptor Antagonists", <i>J. Auton. Pharmacol.</i> , 1993, 13(1):23-93.
	C5	Regoli, et al., "Receptors and Antagonists for Substance P and Related Peptides", <i>Pharmacol. Rev.</i> , 1994, 46(4):551-599.
	C6	Maggio, et al., "History of Tachykinin Peptides", <i>The Tachykinin Receptors</i> ; ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 1-21.
	C7	Nakanishi, S., "Mammalian Tachykinin Receptors", <i>Annu. Rev. Neurosci.</i> , 1991, 14:123-136.
	C8	Bellucci, et al., "Pharmacological Profiles of the Novel Mammalian Tachykinin, Hemokinin 1", <i>Br. J. Pharmacol.</i> , 2002, 135(1):266-274.
	C9	Burcher, et al., "Autoradiographic Localization of Receptors in Peripheral Tissues", <i>The Tachykinin Receptors</i> , ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 125-163.
	C10	Krause, et al., "Molecular Biology of Receptors", <i>The Tachykinin Receptors</i> ; ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 165-218.
	C11	Longmore, et al., "Neurokinin Receptors", <i>Drug News Perspect.</i> 1995, 8 (1):5-23.
	C12	Kucharczyk, N., "Tachykinin Antagonists in Development", <i>Exp. Opin. Invest. Drugs</i> , 1995, 4 (4):299-311.
	C13	Elliott, et al., "Neurokinin Receptor Antagonists", <i>Exp. Opin. Ther. Pat.</i> , 1997, 7 (1):43-54.
	C14	Longmore, et al., "Neurokinin-Receptor Antagonists: Pharmacological Tools and Therapeutic Drugs", <i>Can. J. Physiol. Pharmacol.</i> , 1997, 75:612-621.
	C15	Gerspacher, et al., "Dual Neurokinin NK <sub>1</sub> /NK <sub>2</sub> Receptor Antagonists", <i>Drugs Future</i> , 1999, 24(8):883-892.
	C16	Kudlacz, et al., "In Vitro and In Vivo Characterization of MDL 105, 212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonists", <i>J. Pharmacol. Exp. Ther.</i> , 1996, 277(2):840-851.
FTP	C17	Ramsey, et al., "Pharmacological Characterization of ZD6021: A Novel, Orally Active Antagonist of the Tachykinin Receptors", <i>J. Pharmacol. Exp. Ther.</i> , 2001 298(1):307-315.



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
C18	Gerspacher, et al., "N-[(R, R)-(E)-1-(4-Chloro-benzyl)-3-(2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide: An Orally Active Neuropeptide NK <sub>1</sub> /NK <sub>2</sub> Antagonist", <i>Bioorg. Med. Chem. Lett.</i> , 2000, 10: 1467-1470.	
C19	Shih, et al., "Design and Synthesis of the Novel and Orally Active Dual NK <sub>1</sub> and NK <sub>2</sub> Antagonist Sch 205528", <i>Abstract, Books of Abstracts.- Am. Chem. Soc.</i> , 2000, MEDI-129.	
C20	Bernstein, et al., "Discovery of Novel, Orally Active Dual NK <sub>1</sub> /NK <sub>2</sub> Antagonists", <i>Bioorg. Med. Chem. Lett.</i> , 2001, 11: 2769-2773.	
C21	Ting, et al., "Identification of a Novel 1'-[5-((3,5-dichlorobenzoyl)methylamino)-3-(3,4-dichlorophenyl)-4-methoxyimino]pentyl]-2-oxo-(1,4'-bipiperidine) as a Dual NK <sub>1</sub> /NK <sub>2</sub> Antagonist", <i>Bioorg. Med. Chem. Lett.</i> , 2002, 12: 2125-2128.	
C22	Nishi, T., "Synthetic Studies for the Novel Morpholine and Oxazolidine-Based Tachykinin Receptor Antagonists", <i>Yuki Gosei Kagaku Kyokaishi</i> , 2002, 60(7):657-667.	
C23	Ford-Hutchinson, et al., "Novel Therapeutic Strategies for the Treatment of Human Bronchial Asthma", <i>Drug News Perspect.</i> , 1992, 5(9):542-549.	
C24	Geppetti, et al., "New Aspects on the Role of Kinins in Neurogenic Inflammation", <i>Can. J. Physiol. Pharmacol.</i> , 1995, 73:843-847.	
C25	Advenier, et al., "The Role of Tachykinin Receptor Antagonists in the Prevention of Bronchial Hyperresponsiveness, Airway Inflammation and Cough", <i>Eur. Respir. J.</i> , 1997, 10(8):1892-1906.	
C26	Chapman, et al., "Tachykinins in the Lung", <i>Drug News Perspect</i> , 1998, 11(8):480-489.	
C27	Murai, et al., "Effects of FK224, a Novel Compound NK <sub>1</sub> and NK <sub>2</sub> Receptor Antagonist, on Airway Constriction and Airway Edema Induced by Neurokinins and Sensory Nerve Stimulation in Guinea Pigs", <i>J. Pharmacol. Exp. Ther.</i> , 1992, 262(1):403-408.	
C28	Joos, et al., "The effect of Inhaled FK224, a Tachykinin NK <sub>1</sub> and NK <sub>2</sub> Receptor Antagonist, on Neurokinin A-Induced Bronchoconstriction in Asthmatics", <i>Am. J. Respir. Crit. Care Med.</i> , 1996, 153(6):1781-1784.	
C29	Joos, et al., "Tachykinin Receptors Antagonists: Potential in Airways Diseases", <i>Curr. Opin. Pharmacol.</i> , 2001, 1(3):235-241.	
C30	Gerspacher, et al., "Dual Neurokinin NK <sub>1</sub> /NK <sub>2</sub> Antagonists: N-[(R, R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N'-methylhydrazinol]-N-[(R)-2-oxo-azepan-3-yl]propionamides", <i>Bioorg. Med. Chem. Lett.</i> , 2001, 11(23):3081-3084.	

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Liona T. Powers	Date Considered	11/24/04
--------------------	-----------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.